MAMarie Alexandre

Marie Alexandre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie Alexandre has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates

    by Romain Marlin, Mireille Centlivre, Laetitia Bossevot, Anne-Sophie Gallouët, Marie Alexandre, Delphine Planas, Mariangela Cavarelli, Isabelle Staropoli, Wesley Gros, Mathieu Surenaud, et al.

  • Open Access

    Joint mechanistic modeling of viral and antibody responses to vaccines in non-human primates to quantify SARS-CoV-2 mechanistic correlates of protection

    by Marie Alexandre, Romain Marlin, Laetitia Bossevot, Mariangela Cavarelli, Nathalie Dereuddre-Bosquet, Francis Relouzat, Mireille Centlivre, Roger Le Grand, Rodolphe Thiébaut, Yves Lévy, et al.

    In a global SARS-CoV-2 landscape of hybrid immunity resulting from a vaccinated worldwide population and the emergence of new variants able to escape immunity, the identification and quantification of correlates of protection (CoPs) is crucial for the adaptation of next-generation SARS-CoV-2 vaccines. Antibodies and their neutralizing capacity have been identified as reliable mechanistic CoPs. Here, we proposed an original mechanistic model jointly describing viral and antibody dynamics, and their mutual interactions, observed after SARS-CoV-2 infection in non-human primates (NHPs) with distinct immunological backgrounds. From the model, the concentration of neutralizing antibodies being protective against viral infection spreading was derived using the reproduction number. Counterfactual simulations were also performed to better understand and validate immune mechanisms driving immune control. The model was estimated on viral, binding (bAb), and neutralizing (nAb) antibody dynamics, with data collected in 34 naive and convalescent NHPs. Animals were involved in a preclinical study evaluating two next-generation protein-based vaccines targeting the RBD of the Spike protein to CD40-expressing cells, and the original BNT162b2 mRNA vaccine against Delta SARS-CoV-2 infection. Our model validated the functionality of nAb to neutralize viruses as the primary mechanism of protection. An inhibitory antibody concentration against Delta variant of 20 AU/mL was deemed protective against Delta infection in naive animals. Moreover, we showed the strong benefit of hybrid immunity to induce faster and more protective antibody responses pointing out the crucial role of the memory B-cell immune response in viral control. Finally, an additional effect of natural immunity beyond antibodies and enhancing the elimination of infected cells was identified, suggesting the potential role of the T-cell response in viral control. Our model showed the benefit of combining information from both viral and antibody responses to better qualitatively and quantitatively inform on their protective capacity against Delta SARS-CoV-2 infection.

  • Open Access

    Defining Optimal Vaccine Features for Pandemic Preparedness: An Individual-Based Model Bridging Within- and Between-Host Dynamics

    by Yiqing Xia, Marie Alexandre, Rodolphe Thiébaut, Mathieu Maheu-Giroux, Mélanie Prague

    Background: Disease X, a yet-to-be-identified pathogen of pandemic potential, emphasize the need for proactive surveillance and preparedness. Developing prototype vaccines for representative pathogens is crucial to achieve this goal. A “100 Day Mission” roadmap was proposed to ensure equitable vaccine access within 100 days. This study aims to identify desired vaccine features needed to control future SARS-CoV-2-like pathogens. Methods: An individual-based transmission model was developed, integrating viral load and antibody kinetics. Various combinations of the virus’s basic reproduction number (R0) and vaccine features were examined: 1) the concentration of antibodies required to achieve 50% of the vaccine's theoretical maximum protective effect (EC50), 2) plasma-secreting cell half-life, and 3) the vaccine’s impact on the virus's infection rate of target cells. Their impacts on infections and hospitalizations were quantified over 18 months in a population of 10,000. Random or age-prioritized vaccine rollout strategy began on Day 100, without supply constraints. Results: Vaccines with the same features as the currently available Bnt162b2 vaccine could avert 23-47% of cases and 32-61% of hospitalizations, compared to no vaccine. The fraction of averted cases/hospitalized decreased with increasing R0. Lowering EC50 or extending the plasma-secreting cells’ half-life reduced transmission. However, further improvements beyond an EC50 ≤3 and plasma-secreting cell half-life ≥1 year resulted in minor population-level improvements. Changes to the virus-target cell infection rate had minimal impacts on vaccine effectiveness. Vaccine effectiveness did not vary largely by allocation strategy. Conclusions: Vaccine development should focus on improving the EC50, followed by extending the half-life of plasma-secreting cells.

  • Definition of Virological Endpoints Improving the Design of HIV Cure Strategies Using Analytical Antiretroviral Treatment Interruption

    by Marie Alexandre, Mélanie Prague, Edouard Lhomme, Jean-Daniel Lelièvre, Linda Wittkop, Laura Richert, Yves Lévy, Rodolphe Thiébaut

    Background: Analytical treatment interruption (ATI) is the gold standard in HIV research for assessing the capability of new therapeutic strategies to control viremia without antiretroviral treatment (ART). The viral setpoint is commonly used as endpoint to evaluate their efficacy. However, in line with recommendations from a consensus meeting, to minimize the risk of increased viremia without ART, trials often implement short ATI phases and stringent virological ART restart criteria. This approach can limit the accurate observation of the setpoint. Methods: We analyzed viral dynamics in 235 people with HIV from 3 trials, examining virological criteria during ATI phases. Time-related (eg time to rebound, peak, and setpoint) and viral load magnitude–related criteria (peak, setpoint, and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify (1) surrogate endpoints for setpoint and (2) optimal virological ART restart criteria mitigating the risks of ART interruption and the evaluation of viral control. Results: Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC the most strongly correlated with the setpoint, with correlations >0.70. A threshold >100 000 copies/mL for 2 consecutive measures is requested as a virological ART restart criterion. Conclusions: Our results are in line with recommendations and emphasize the benefits of an ATI phase >12 weeks, with regular monitoring, and a virological ART restart criterion of 10 000 copies/mL to limit the risk for patients while capturing enough information to keep nAUC as an optimal proxy to the setpoint.


  • Open Access

    Definition of viroIogical endpoints improving the design of HIV cure strategies using analytical antiretroviral treatment interruption

    by Marie Alexandre, Mélanie Prague, Edouard Lhomme, Jean-Daniel Lelievre, Linda Wittkop, Laura Richert, Yves Lévy, Rodolphe Thiébaut

    Background Analytical treatment interruption (ATI) is the gold standard in HIV research to validate the ability of novel therapeutic strategies to long-term control viremia without antiretroviral treatment (ART). Viral setpoint is commonly used as endpoint to evaluate their efficacy. However, to mitigate higher viremia risk without ART, trials use short ATI phases and strict virological ART re-start criteria, compromising the observation of the setpoint. Methods We analyzed viral dynamics in 235 HIV-infected participants from three trials, examining various virological criteria during ATI phases. Time-related (e.g. time to rebound, peak and setpoint) and VL magnitude-related criteria (peak, setpoint and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify surrogate endpoints for setpoints. Additional correlation analyzes were performed to identify optimal virological ART re-start criteria mitigating the risks of ART interruption and the evaluation of viral control. Results Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC identified as the criterion most strongly correlated with the setpoint, with correlations higher than 0.70. A threshold of at least 100,000 copies/mL for two consecutive VL measurements is requested as virological ART re-start criteria to keep strong correlations between the setpoint and nAUC. Conclusions Our results emphasize the benefits of an ATI phase longer than 12 weeks, with regular monitoring, and a VL threshold of 100,000 copies/mL as virological ART re-start criteria to limit the risk for patients while capturing enough information to keep nAUC as an optimal proxy for the setpoint.


  • Open Access

    Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

    by Marie Alexandre, Mélanie Prague, Chelsea McLean, Viki Bockstal, Macaya Douoguih, Rodolphe Thiébaut, Thierry Van Effelterre, Laura Solforosi, Anna Dari

    The persistence of the long-term immune response induced by the heterologous Ad26.ZEBOV, MVA-BN-Filo two-dose vaccination regimen against Ebola has been investigated in several clinical trials. Longitudinal data on IgG-binding antibody concentrations were analyzed from 487 participants enrolled in six Phase I and Phase II clinical trials conducted by the EBOVAC1 and EBOVAC2 consortia. A model based on ordinary differential equations describing the dynamics of antibodies and short- and long-lived antibody-secreting cells (ASCs) was used to model the humoral response from 7 days after the second vaccination to a follow-up period of 2 years. Using a population-based approach, we first assessed the robustness of the model, which was originally estimated based on Phase I data, against all data. Then we assessed the longevity of the humoral response and identified factors that influence these dynamics. We estimated a half-life of the long-lived ASC of at least 15 years and found an influence of geographic region, sex, and age on the humoral response dynamics, with longer antibody persistence in Europeans and women and higher production of antibodies in younger participants.


  • Open Access

    Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates

    by Aurélien Marc, Romain Marlin, Flora Donati, Mélanie Prague, Marion Kerioui, Cécile Hérate, Marie Alexandre, Nathalie Dereuddre-Bosquet, Julie Bertrand, Vanessa Contreras, et al.

    The impact of variants of concern (VoC) on SARS-CoV-2 viral dynamics remains poorly understood and essentially relies on observational studies subject to various sorts of biases. In contrast, experimental models of infection constitute a powerful model to perform controlled comparisons of the viral dynamics observed with VoC and better quantify how VoC escape from the immune response. Here we used molecular and infectious viral load of 78 cynomolgus macaques to characterize in detail the effects of VoC on viral dynamics. We first developed a mathematical model that recapitulate the observed dynamics, and we found that the best model describing the data assumed a rapid antigen-dependent stimulation of the immune response leading to a rapid reduction of viral infectivity. When compared with the historical variant, all VoC except beta were associated with an escape from this immune response, and this effect was particularly sensitive for delta and omicron variant (p−6 for both). Interestingly, delta variant was associated with a 1.8-fold increased viral production rate (p = 0.046), while conversely omicron variant was associated with a 14-fold reduction in viral production rate (p−6). During a natural infection, our models predict that delta variant is associated with a higher peak viral RNA than omicron variant (7.6 log10 copies/mL 95% CI 6.8–8 for delta; 5.6 log10 copies/mL 95% CI 4.8–6.3 for omicron) while having similar peak infectious titers (3.7 log10 PFU/mL 95% CI 2.4–4.6 for delta; 2.8 log10 PFU/mL 95% CI 1.9–3.8 for omicron). These results provide a detailed picture of the effects of VoC on total and infectious viral load and may help understand some differences observed in the patterns of viral transmission of these viruses.


  • Open Access

    Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates

    by Aurélien Marc, Romain Marlin, Flora Donati, Mélanie Prague, Marion Kerioui, Cécile Hérate, Marie Alexandre, Nathalie Dereuddre-Bosquet, Julie Bertrand, Vanessa Contreras, et al.

    The impact of variants of concern (VoC) on SARS-CoV-2 viral dynamics remains poorly understood and essentially relies on observational studies subject to various sorts of biases. In contrast, experimental models of infection constitute a powerful model to perform controlled comparisons of the viral dynamics observed with VoC and better quantify how VoC escape from the immune response. Here we used molecular and infectious viral load of 78 cynomolgus macaques to characterize in detail the effects of VoC on viral dynamics. We first developed a mathematical model that recapitulate the observed dynamics, and we found that the best model describing the data assumed a rapid antigen-dependent stimulation of the immune response leading to a rapid reduction of viral infectivity. When compared with the historical variant, all VoC except beta were associated with an escape from this immune response, and this effect was particularly sensitive for delta and omicron variant (p−6 for both). Interestingly, delta variant was associated with a 1.8-fold increased viral production rate (p=0.046), while conversely omicron variant was associated with a 14-fold reduction in viral production rate (p−6 ). During a natural infection, our models predict that delta variant is associated with a higher peak viral RNA than omicron variant (7.6 log 10 copies/mL 95% CI 6.8 – 8 for delta; 5.6 log 10 copies/mL 95% CI 4.8 – 6.3 for omicron) while having similar peak infectious titers (3.7 log 10 PFU/mL 95% CI 2.4 – 4.6 for delta; 2.8 log 10 PFU/mL 95% CI 1.9 – 3.8 for omicron). These results provide a detailed picture of the effects of VoC on total and infectious viral load and may help understand some differences observed in the patterns of viral transmission of these viruses.


  • Open Access

    Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection

    by Marie Alexandre, Romain Marlin, Mélanie Prague, Severin Coleon, Nidhal Kahlaoui, Sylvain Cardinaud, Thibaut Naninck, Benoit Delache, Mathieu Surenaud, Mathilde Galhaut, et al.

    The definition of correlates of protection is critical for the development of next-generation SARS-CoV-2 vaccine platforms. Here, we propose a model-based approach for identifying mechanistic correlates of protection based on mathematical modelling of viral dynamics and data mining of immunological markers. The application to three different studies in non-human primates evaluating SARS-CoV-2 vaccines based on CD40-targeting, two-component spike nanoparticle and mRNA 1273 identifies and quantifies two main mechanisms that are a decrease of rate of cell infection and an increase in clearance of infected cells. Inhibition of RBD binding to ACE2 appears to be a robust mechanistic correlate of protection across the three vaccine platforms although not capturing the whole biological vaccine effect. The model shows that RBD/ACE2 binding inhibition represents a strong mechanism of protection which required significant reduction in blocking potency to effectively compromise the control of viral replication.


  • Open Access

    SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines

    by Marie Alexandre, Romain Marlin, Mélanie Prague, Séverin Coleon, Nidhal Kahlaoui, Sylvain Cardinaud, Thibaut Naninck, Benoit Delache, Mathieu Surenaud, Mathilde Galhaut, et al.

    The definition of correlates of protection is critical for the development of next generation SARS-CoV-2 vaccine platforms. Here, we propose a new framework for identifying mechanistic correlates of protection based on mathematical modelling of viral dynamics and data mining of immunological markers. The application to three different studies in non-human primates evaluating SARS-CoV-2 vaccines based on CD40-targeting, two-component spike nanoparticle and mRNA 1273 identifies and quantifies two main mechanisms that are a decrease of rate of cell infection and an increase in clearance of infected cells. Inhibition of RBD binding to ACE2 appears to be a robust mechanistic correlate of protection across the three vaccine platforms although not capturing the whole biological vaccine effect. The model shows that RBD/ACE2 binding inhibition represents a strong mechanism of protection which required significant reduction in blocking potency to effectively compromise the control of viral replication. One Sentence Summary: A framework for modelling the immune control of viral dynamics is applied to quantify the effect of several SARS-CoV-2 vaccine platforms and to define mechanistic correlates of protection.